Entera Bio Ltd. (LS:A2JQXP) Financings

Entera Bio Ltd.

Financings

RaiseDate
Private placement of ordinary shares and pre-funded warrants
Closed: US$275M raised · US$2.04 a share · Leerink Partners +5
Dealers: Leerink Partners (lead), Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital, Canaccord Genuity
Buyers: BVF Partners L.P. (led the private placement; granted the right to designate two directors); Longitude Capital; Vivo Capital; TCGX; Spruce Street Capital; Venrock Healthcare Capital Partners; RA Capital Management; Perceptive Advisors; Driehaus Capital Management; Logos Capital; Catalio Capital Management
Use of proceeds: Fund EB613 Phase 3 program through NDA submission, advance EB612 into the clinic with OPKO, and extend cash runway into 2030
Aug 7, 2026
Strategic investment of ordinary shares
Closed: US$2.17 a share
Buyers: OPKO (3,685,226 ordinary shares at $2.17 per share)
Use of proceeds: To fund Entera's 40% share of costs of the oral GLP-1/glucagon program through Phase 1
Mar 17, 2025

Read by 6ix AI from the company's releases